Drug intelligence / Profile preview

Valcor

Development stage: Unknown
Lead developer: Zoetis
Modality: Small Molecules
Administration: Subcutaneous

Overview

Valcor is a fixed-dose combination injectable endectocide for cattle, marketed in the United States. It contains 0.2 mg/kg doramectin and 6.0 mg/kg levamisole hydrochloride. Administered subcutaneously, it is effective against various ectoparasites such as Rhipicephalus microplus (ticks) and sucking lice (Linognathus vituli). The drug has demonstrated safety in cattle, including reproductive safety in heifers.

Brand names: ValcorDectomax V

Targets

GluCl (Glutamate-gated chloride channel)

Beyond the preview

Go deeper on Valcor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Valcor.

Explore the full profile